Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1 alpha inactivation

作者：Wang Tong Hong; Wu Chi Hao; Yeh Chau Ting; Su Shih Chi; Hsia Shih Min; Liang Kung Hao; Chen Chin Chuan; Hsueh Chuen^*; Chen Chi Yuan^*

来源：Oncotarget, 2017, 8(47): 82280-82293.

DOI：10.18632/oncotarget.19316

• melatonin
• hepatocellular carcinoma
• epithelial-mesenchymal transition
• lncRNA-CPS1-IT1
• HIF-1 alpha

Melatonin is the primary pineal hormone that relays light/dark cycle information to the circadian system. It was recently reported to exert intrinsic antitumor activity in various cancers. However, the regulatory mechanisms underlying the antitumor activity of melatonin are poorly understood. Moreover, a limited number of studies have addressed the role of melatonin in hepatocellular carcinoma (HCC), a major life-threatening malignancy in both sexes in Taiwan. In this study, we investigated the antitumor effects of melatonin in HCC and explored the regulatory mechanisms underlying these effects. We observed that melatonin significantly inhibited the proliferation, migration, and invasion of HCC cells and significantly induced the expression of the transcription factor FOXA2 in HCC cells. This increase in FOXA2 expression resulted in upregulation of lncRNA-CPS1 intronic transcript 1 (CPS1-IT1), which reduced HIF-1 alpha activity and consequently resulted in the suppression of epithelial-mesenchymal transition (EMT) progression and HCC metastasis. Furthermore, the results of the in vivo experiments confirmed that melatonin exerts tumor suppressive effects by reducing tumor growth. In conclusion, our findings suggested that melatonin inhibited HCC progression by reducing lncRNA-CPS-1IT1-mediated EMT suppression and indicated that melatonin could be a promising treatment for HCC.

• 出版日期2017-10-10
• 单位长春大学